Abstract: The urothelium of the bladder has long been recognized as a protective barrier between detrusor and urine. In recent years, it has become more evident that the urothelium plays a role as an active source of mediators. The urothelium can release neurotransmitters and modulators such as acetylcholine, ATP, nitric oxide, prostaglandins and neuropeptides. They exert both excitatory and inhibitory effects in modulating urinary tract motility. In addition, several studies have reported the existence of an urothelium-derived unknown inhibitory factor in the urinary bladder. By the use of a new serial cascade superfusion bioassay on guinea pig ureter, recent studies confirm that the guinea pig bladder urothelium releases a substance with inhibitory bioactivity, which was resistant to treatment with nitric oxide synthase inhibitor and cyclooxygenase inhibitor and to adenosine A1/A2 receptor blockade. Lately, a marked and quickly inactivated novel release of PGD 2 from the bladder urothelium was discovered, together with localization of prostaglandin D synthase therein. PGD 2 was found to have an inhibitory influence on nerve-induced contractions in guinea pig urinary bladder and on spontaneous contractions in the out-flow region. An altered release of excitatory and inhibitory factors is likely to play an important part in bladder motility disturbances, of which the prostanoids are a notable group. Due to the fact that the bladder is relaxed 99% of the time, not only excitatory mechanisms in the bladder are necessary to study, but also inhibitory mechanisms need considerable attention, which will contribute to the discovery of new targets to treat bladder motility disorders.
Urothelium functions in general
The urothelium is a transitional epithelium lining on the internal surface of the urinary bladder, which becomes thinner and flatter during bladder distension and folds when the bladder is empty. The urothelium has three distinct layers formed separately by the big apical umbrella cells, the intermediate cells and the small basal cells, respectively [1] . The urothelium has more sophisticated functions rather than simply forming a barrier between urine and underlying tissues. The role of the urothelium involves transport, regeneration, sensory functions as well as secretion of mediators. The urothelium maintains high electrical resistance allowing only active ion transport between urine and blood [2] . Selective and non-selective ion channels exist on both the apical and the basal sides of the urothelium [3, 4] . Water is transported across the urothelium via aquaporins expressed by urothelial cells [5] . The small basal cells of the urothelium have properties typically seen in stem cells, such as slow turnover rate [6] . Besides, the urothelium is able to sense both physical and chemical stimuli. Afferent and efferent nerves are localized next to the urothelium [7, 8] . Numerous receptors are expressed in the urothelium, for example cholinergic, adrenergic, purinergic and peptidergic receptors. TRP channels, oestrogen receptors, as well as factors associated with the nitric oxide pathways are also expressed in urothelium [9] [10] [11] . Receptors for prostaglandins have also been found in the urothelium [12] . Recently, the distribution of cannabinoid receptor 2 on sensory nerves and in the urothelium was confirmed [13] , and cannabinoids increased micturition intervals, volumes, threshold and flow pressures in awake rats [14] . The urothelium is a source for the release of mediators such as ATP, acetylcholine, prostanoids, peptides, cytokines and so on [8, 15] . Meanwhile, the urothelium is also releasing gaseous neurotransmitters such as nitric oxide [16, 17] and hydrogen sulphide (H 2 S). A recent study has shown that human urothelium expresses both cystathionine synthase (CBS) and cystathionine lyase (CSE) enzymes, of which CBS-derived H 2 S seems to be the major source of H 2 S [18] . However, exactly which compartments of the urothelium that are responsible for the release of certain mediators is still unclear.
Urothelium released unknown inhibitory factor(s)
The detrusor muscle of the bladder is relaxed 99% of the time; this indicates the importance of searching for the endogenous inhibitory principles in the urinary tract. Besides the well-known inhibitory mediators such as nitric oxide, there is an increasing body of evidence showing a release of a urothelium-derived inhibitory factor. In the late 1980s, Maggi and colleagues noticed that when the urothelium was intact, the contractile responses induced by substance P were smaller compared with urothelium-denuded tissues in the guinea pig urinary bladder [19] . Later, it was shown that in the pig urinary bladder, there was an enhanced response to the contractile substances if the urothelium was removed; however, the responses returned to a lower amplitude when a second urothelium-intact tissue was co-incubated [20] . Chess-Williams' group showed the existence of a diffusible urothelium-derived inhibitory factor (UDIF) in pig urinary bladder using sandwich-type bioassay experiments, where the factor appeared to be neither nitric oxide, a cyclooxygenase product, a catecholamine, adenosine, GABA nor an EDHF sensitive to apamin [20, 21] . UDIF-like effects were also observed in mouse urinary bladder by electrophysiology [22] and by quantitative analysis of contractile responses in human urinary bladder [23] . The study using human bladder strips showed that the factor was distinct from nitric oxide and it persisted in the presence of beta-adrenoceptor blockade or cyclooxygenase inhibition. The existence of the urothelium-derived inhibitory factor in the guinea pig urinary bladder was also demonstrated by assay on the spontaneous contracted guinea pig ureters in a cascade superfusion bioassay system, which offers further possibilities to identify the factor [24] . The results indicated a transmissible inhibitory factor over a significant distance and seemed less likely to be nitric oxide, nitrite, an adenosine receptor agonist or cyclooxygenase products. In addition to the UDIF, Andersson's group obtained evidence for the release of a non-urothelium-dependent relaxant mediator from urinary bladder, when they co-incubated the urothelium-intact bladder with an endothelium-denuded rat aorta strip [25, 26] . Similar bladder-derived relaxant factor was also shown in the rat, using urinary bladder as assay tissue by coaxial bioassay system [27] . The nature of UDIF and the bladder-derived urothelium-independent relaxant factor(s) has not been elucidated.
Inhibitory activities induced by prostaglandins
Release of prostaglandins in the urinary bladder. Prostanoids as one of the mediators released from urinary bladder have been known for many years. It is well accepted that prostanoids are produced locally within the smooth muscle and mucosa in human beings and other species [28] [29] [30] . In addition to release of the prostaglandins E and F series, some studies of prostaglandin secretion showed significant release of PGD 2 from pieces of challenged or normal rat urinary bladder [31, 32] as well as from the normal guinea pig urinary bladder [33] . Both HPLC and immunohistochemistry studies Fig. 3 . Schematic depicting the distribution of PGD 2 and DP 1 in the bladder wall. PGD 2 is released from urothelium and suburothelium and activates P 1 receptors on the urothelial cells, interstitial cells and smooth muscle cells which lead to relaxation of the smooth muscle in guinea pig urinary bladder.
showed that the source of PGD 2 production was from urothelium/suburothelium [33, 34] . Antibody against PGD synthase was used to detect the location of PGD 2 production in guinea pig and human urinary bladders. Strong immunoreactivity for PGD synthase in the basal urothelium and suburothelium was seen in the guinea pig ( fig. 1 ) and human bladder (preliminary data from our laboratory).
Inhibitory function of prostaglandins in the urinary bladder
Expression of EP 2 receptors has been shown in guinea pig bladder, and expression of all four EP 1-4 receptor subtypes has been shown in canine bladder [35, 36] . In general, prostaglandin E and F series have excitatory effects in modulating bladder motility. However, recent studies using knockout animals and selective antagonists have shown a more complex function of PGE 2 due to different EP receptor characteristics. EP 1 knockout mice did not respond to intravesical PGE 2 instillation compared with wild-type mice [37] . In normal rats, an EP 1 antagonist significantly increased the bladder capacity, voiding volume and micturition interval [38] . Urodynamic tests of EP 3 knockout mice revealed an enhanced bladder capacity in the basal state and reduced hyperactivity response to application of PGE 2 [39] . In rats, intravesical instillation of the EP 4 antagonist MF191 suppressed bladder overactivity induced by PGE 2 and cyclophosphamide [40] . In contrast to PGE 2 , a recent study from our laboratory showed that PGD 2 inhibited contractile responses induced by electrical field stimulation, ATP or ACh in the guinea pig urinary bladder strips. Also, the DP 1 receptors were found in smooth muscle of the bladder wall with a dominant localization to smooth muscle membranes [41] . We like to suggest that the inhibitory effect by PGD 2 is mediated via DP 1 receptors ( fig. 2 ). This study also showed expression of DP 1 receptors on the membrane of urothelial cells and on the interstitial cell-like profiles in the deep lamina propria. The sites of expression fit well with the location of prostaglandin D synthase (PGDS) in the guinea pig urinary bladder. The intracellular effects of activating DP 1 receptors in the urothelium and interstitial cells are still unknown. The underlying mechanism in the interaction between urothelium and suburothelium merits future studies, and if proven would add to the concept of signalling between the urothelium, interstitial cells and muscle [9, 42, 43] ( fig. 3 ).
Conclusions and future perspectives
The urinary bladder is a hollow smooth muscle organ which remains relaxed for an absolute majority of the time. The balance between excitatory and inhibitory modulations is essential to maintain the function of urine storage and micturition. It is reasonable to suggest that the relaxation of the bladder requires constant release of inhibitory factor(s) and PGD 2 is a mediator that has such qualities. Under a certain degree of distension during urine storage, calcium entry is just enough in the urothelium/suburothelium to activate the release of inhibitory factors maintaining the expansion. On the other hand, a high degree of stretching likely causes more calcium entry that leads to the release of excitatory factors such as ATP, which triggers micturition. Bladder motility disorders are thus likely to have a component of excitatory and inhibitory imbalance. The study of the inhibitory factor(s) released from urinary bladder not only aids us in the understanding of the urinary tract physiology but in the long run also contributes to the quest for new treatments for bladder motility disorders.
